Last week, WPD met with Worldwide Clinical Trials, a world-renowned Contract Research Organization engaged to coordinate and supervise the start-up of WPD’s Phase 1 and 2 clinical trials on Berubicin.

The discussions indicated that the Berubicin adult trial is expected to commence in February 2021 and the children multicenter pediatric phase I clinical trial later in 2021.

About 60% of the program budget is expected to be refunded by a grant already awarded to WPD by The National Center for Research and Development based in Poland under the European Union’s Smart Growth Operational Program.

https://www.globenewswire.com/news-release/2020/10/26/2114173/0/en/WPD-Pharmaceuticals-Provides-Update-On-Berubicin-Drug-Candidate-in-Celebration-of-National-Brain-Cancer-Day-in-Canada.html